Common germline polymorphisms associated with breast cancer-specific survival.
Pirie A., Guo Q., Kraft P., Canisius S., Eccles DM., Rahman N., Nevanlinna H., Chen C., Khan S., Tyrer J., Bolla MK., Wang Q., Dennis J., Michailidou K., Lush M., Dunning AM., Shah M., Czene K., Darabi H., Eriksson M., Lambrechts D., Weltens C., Leunen K., van Ongeval C., Nordestgaard BG., Nielsen SF., Flyger H., Rudolph A., Seibold P., Flesch-Janys D., Blomqvist C., Aittomäki K., Fagerholm R., Muranen TA., Olsen JE., Hallberg E., Vachon C., Knight JA., Glendon G., Mulligan AM., Broeks A., Cornelissen S., Haiman CA., Henderson BE., Schumacher F., Le Marchand L., Hopper JL., Tsimiklis H., Apicella C., Southey MC., Cross SS., Reed MW., Giles GG., Milne RL., McLean C., Winqvist R., Pylkäs K., Jukkola-Vuorinen A., Grip M., Hooning MJ., Hollestelle A., Martens JW., van den Ouweland AM., Marme F., Schneeweiss A., Yang R., Burwinkel B., Figueroa J., Chanock SJ., Lissowska J., Sawyer EJ., Tomlinson I., Kerin MJ., Miller N., Brenner H., Butterbach K., Holleczek B., Kataja V., Kosma V-M., Hartikainen JM., Li J., Brand JS., Humphreys K., Devilee P., Tollenaar RA., Seynaeve C., Radice P., Peterlongo P., Manoukian S., Ficarazzi F., Beckmann MW., Hein A., Ekici AB., Balleine R., Phillips K-A., kConFab Investigators None., Benitez J., Zamora MP., Perez JIA., Menéndez P., Jakubowska A., Lubinski J., Gronwald J., Durda K., Hamann U., Kabisch M., Ulmer HU., Rüdiger T., Margolin S., Kristensen V., Nord S., NBCS Investigators None., Evans DG., Abraham J., Earl H., Poole CJ., Hiller L., Dunn JA., Bowden S., Yang R., Campa D., Diver WR., Gapstur SM., Gaudet MM., Hankinson S., Hoover RN., Hüsing A., Kaaks R., Machiela MJ., Willett W., Barrdahl M., Canzian F., Chin S-F., Caldas C., Hunter DJ., Lindstrom S., Garcia-Closas M., Couch FJ., Chenevix-Trench G., Mannermaa A., Andrulis IL., Hall P., Chang-Claude J., Easton DF., Bojesen SE., Cox A., Fasching PA., Pharoah PD., Schmidt MK.
INTRODUCTION: Previous studies have identified common germline variants nominally associated with breast cancer survival. These associations have not been widely replicated in further studies. The purpose of this study was to evaluate the association of previously reported SNPs with breast cancer-specific survival using data from a pooled analysis of eight breast cancer survival genome-wide association studies (GWAS) from the Breast Cancer Association Consortium. METHODS: A literature review was conducted of all previously published associations between common germline variants and three survival outcomes: breast cancer-specific survival, overall survival and disease-free survival. All associations that reached the nominal significance level of P value <0.05 were included. Single nucleotide polymorphisms that had been previously reported as nominally associated with at least one survival outcome were evaluated in the pooled analysis of over 37,000 breast cancer cases for association with breast cancer-specific survival. Previous associations were evaluated using a one-sided test based on the reported direction of effect. RESULTS: Fifty-six variants from 45 previous publications were evaluated in the meta-analysis. Fifty-four of these were evaluated in the full set of 37,954 breast cancer cases with 2,900 events and the two additional variants were evaluated in a reduced sample size of 30,000 samples in order to ensure independence from the previously published studies. Five variants reached nominal significance (P <0.05) in the pooled GWAS data compared to 2.8 expected under the null hypothesis. Seven additional variants were associated (P <0.05) with ER-positive disease. CONCLUSIONS: Although no variants reached genome-wide significance (P <5 x 10(-8)), these results suggest that there is some evidence of association between candidate common germline variants and breast cancer prognosis. Larger studies from multinational collaborations are necessary to increase the power to detect associations, between common variants and prognosis, at more stringent significance levels.